PLASMA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IS ASSOCIATED WITH LP(A) IN TYPE 2 DIABETIC PATIENTS

被引：2
|
作者：
Nekaies, Y. [1 ]
Baudin, B. [2 ,3 ]
Sakly, M. [1 ]
Attia, N. [1 ]
机构：
[1] Univ Carthage, Fac Sci Bizerte, Res Unit Integrated Physiol UR11ES33, Bizerte, Tunisia
[2] Biol & Pathol Pole St Antoine Hosp, Dept Biochem, Paris, France
[3] Fac Pharm Chatenay Malabry, Paris, France
来源：
ATHEROSCLEROSIS | 2015年 / 241卷 / 01期
关键词：
D O I：
10.1016/j.atherosclerosis.2015.04.356
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EAS-0862
引用
收藏
页码：E102 / E102
页数：1
相关论文
共 50 条
  • [1] Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients
    Nekaies, Ymene
    Baudin, Bruno
    Kelbousi, Sami
    Sakly, Mohsen
    Attia, Nebil
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (08) : 1165 - 1170
  • [2] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [3] Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
    Imaralu, Omonzejie E.
    Narasimhulu, Chandrakala Aluganti
    Singal, Pawan K.
    Singla, Dinender K.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (01) : 14 - 25
  • [4] Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes
    Trico, Domenico
    Raggi, Francesco
    Distaso, Mariarosaria
    Ferrannini, Ele
    Solini, Anna
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 190
  • [5] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [6] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
  • [7] Regulation of ENaC by proprotein convertase subtilisin/kexin type 9(PCSK9)
    Sharotri, Vikas
    Snyder, Peter M.
    FASEB JOURNAL, 2010, 24
  • [8] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients
    Torino, Claudia
    Carbone, Federico
    Pizzini, Patrizia
    Mezzatesta, Sabrina
    D'Arrigo, Graziella
    Gori, Mercedes
    Liberale, Luca
    Moriero, Margherita
    Michelauz, Cristina
    Fre, Federica
    Isoppo, Simone
    Gavoci, Aurora
    La Rosa, Federica
    Scuricini, Alessandro
    Tirandi, Amedeo
    Ramoni, Davide
    Mallamaci, Francesca
    Tripepi, Giovanni
    Montecucco, Fabrizio
    Zoccali, Carmine
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (09)
  • [9] Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
    El Khoury, Petra
    Roussel, Ronan
    Fumeron, Frederic
    Abou-Khalil, Yara
    Velho, Gilberto
    Mohammedi, Kamel
    Jacob, Marie-Paule
    Steg, Philippe Gabriel
    Potier, Louis
    Ghaleb, Youmna
    Elbitar, Sandy
    Ragot, Stephanie
    Andreata, Francesco
    Caligiuri, Giusepinna
    Hadjadj, Samy
    Boileau, Catherine
    Marre, Michel
    Abifadel, Marianne
    Varret, Mathilde
    Hansel, Boris
    DIABETES OBESITY & METABOLISM, 2018, 20 (04): : 943 - 953
  • [10] Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Rainer Schulz
    Klaus-Dieter Schlüter
    Ulrich Laufs
    Basic Research in Cardiology, 2015, 110
12345